Bright artificial light produces subsensitivity to clonidine by Dilsaver, Steven C. & Majchrzak, Mark J.
Life Sciences, vol. 42, pp. 597-601 
Printed in the U.S.A. 
Pergamon Journals 
BRIGHT ARTIFICIAL LIGHT PRODUCES SUBSENSITIVITY TO CLONIDINE 
Steven C. Dilsaver', M.D., Mark J. Majchrzak2 
lNeuroscience Program, Department of Psychiatry, College of Medicine, 
Ohio State University, 473 West 12th Avenue, Columbus, Ohio 43201-1228 
2Department of Psychiatry, Mental Health Research Institute, 
University of Michigan, 205 Washtenaw Place, Ann Arbor, Michigan 48109 
(Received in final form December 1, 1987) 
Summary 
The authors used a thermoregulation paradigm to test the 
hypothesis that chronic treatment with bright artificial light 
produces subsensitivity to the hypothermic effects of clonidine, 
an a2-agonist. One week of treatment produced blunting of the 
hypothermic response to clonidine (p < 0.00001). These findings 
are consistent with previous reports that somatic treatments for 
depression produce subsensitivity of the a2-receptor. 
Seasonal Affective Disorder (SAD) is a syndrome characterized by 
recurrent depressions which occur annually (1). This syndrome responds to 
daily treatment with 2 - 6 hours of bright artificial light (l-5). A 
mechanism accounting for the efficacy of this treatment has not been 
identified. 
Deficient noradrenergic neurotransmission is implicated in the 
pathophysiology of endogenous depression (6,7). This could be due to an 
increased density or supersensitivity of a2-receptors (8-11) which, when 
activated, decrease the release of norepinephrine (12,13). 
Materials and Methods 
We used a thermoregulation paradigm to demonstrate that chronic 
treatment with antidepressants produces supersensitivity to the hypothermic 
effects of oxotremorine (14,15). We now use this paradigm to verify that 
bright artificial light produces subsensitivity to the hypothermic effects of 
clonidine (16-19). We also demonstrate that multiple injections of clonidine 
do not produce subsensitivity to subsequent injections of itself. 
The dependent variable in the experiments reported here was change in 
core temperature in response to clonidine HCl, an a2-agonist. These 
receptors are predominantly but not exclusively of presynaptic origin. Core 
temperature was measured using a telemetric thermosensor, the model VM Mini- 
Mitter (Mini-Mitter Co., Sun River, OR). These devices emit radio waves at a 
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frequency detectable using an AM receiver. Information regarding the 
validity of this method is available elsewhere (20). 
Full-spectrum bright artificial light (11,500 lux) was emitted from a 
bank of eight 122 cm long Vitalight tubes suspended 50 cm above the animals. 
The animals were exposed to the light for 24 hours a day for 7 consecutive 
days. 
The light unit used (Duro Test Corp., Bergen, NJ, Model 5599) provides 
full spectrum light of the variety used to treat SAD (1-S). This unit is 
used to treat SAD (2). Temperature under the lights was 23 - 23.5"C. 
Mini-Mitters were implanted into the peritoneal cavities of 10 adult, 
male Sprague-Dawley rats (mean weight + SEM = 391.8 f 14.2 g). The animals 
were allowed five days to recover before beginning experimentation. 
Experiment 1 involved the measurement of the hypothermic response to 
clonidine HCl, 0.10 mg/kg ip, prior to exposure to bright artificial light 
(i.e., at baseline), following one week of light exposure and one week after 
the withdrawal of phototherapy. Core temperature was measured immediately 
prior to the injection of clonidine and every 10 minutes thereafter for 120 
minutes. The animals were subjected to the standard 12 hour light/dark cycle 
during the baseline and withdrawal phases. Experiment 2 involved the 
exposure of animals (mean weight f SEM = 268.6 f 9.9 g) to standard 
fluorescent light at an intensity of 300 lux 24 hours a day for 7 days. This 
was designed to show that changes in circadian rhythms due to light exposure 
per se do not account for our findings. 
Experiment 3 involved the measurement of core temperature in response to 
clonidine HCl, 0.40 mg/kg ip, at baseline and one and two weeks later in 7 
adult, male Sprague-Dawley rats (mean weight f SEM = 243.6 f 5.8 g) not 
exposed to bright, artificial light. These animals were subjected to the 
normal ambient conditions in our vivarium. This involves exposure to 
standard fluorescent light at an intensity of 300 lux between 0600 and 1800. 
The objective of this experiment was to demonstrate that multiple injections 
of clonidine do not alter the thermic responsiveness to itself. The high 
dose of clonidine provided a stringent test of the hypothesis that clonidine 
does not produce subsensitivity to itself when administered weekly. 
Data were assessed for significance using student's paired t-test. All 
measures of variance in the text refer to the standard error of the mean 
(SEM). 
Results 
Experiment 1: Mean core temeprature at baseline was 37.2 + 0.31"C. 
Table I summarizes the mean thermic response over the 12 time points of all 
10 animals. Nine (9) of the 10 animals exhibited blunting of the hypothermic 
response to clonidine at a < 0.04. Further, the mean thermic response of the 
sample, which was -1.22 f 0.15"C prior to light exposure and -0.03 + O.lO"C 
after chronic light treatment, was significantly blunted (p < 0.00009, t = 
6.74, df = 9). One week after the discontinuation of light treatment, the 
mean hypothermic response of the sample increased to -1.16 f 0.14"C. This 
differed significantly from the response during light treatment (p < 0.0003, 
t = 5.80, df = 9) but did not differ from baseline (p < 0.80, t = 0.24, df = 
9). 
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TABLE I 
A B C 
Mean Hypothermic 
Mean Hypothermic Response After 
Response After 1 Week Light 
1 Week of Light Withdrawn 
0.35 f 0.04 -1.92 ? 0.12 
0.07 f 0.04 -1.15 + 0.11 
-0.26 + 0.05 -1.50 + 0.22 
0.21 f 0.04 -1.30 f 0.20 
0.39 + 0.06 -1.49 + 0.12 
0.27 + 0.06 -0.62 + 0.15 
0.00 f 0.05 -0.43 f 0.12 
0.47 + 0.04 -1.05 + 0.16 
-0.29 f 0.07 -0.96 + 0.11 
-0.41 f 0.11 -1.16 f 0.17 
-0.03 f 0.10 -1.16 f 0.14 
Student's paired t-tests of hypothermic responses of indi- 












-0.55 -I 0.12 
-0.69 f 0.08 0.004 
-1.22 + 0.15 
vidual animals (n = 10) to clonidine (0.10 mg/kg ip) at baseline 
(pretreatment), following 7 days of 11,500 lux light treatment, 
and 7 days following withdrawal of light. Core temperature was 













Light, Subsensitivity to Clonidine 599 
n.s. 
Experiment 2: Mean core temperature at baseline was 37.8 f 0.35"C. 
The mean thermic response of the sample before and after treatment with 300 
lux light was -1.4 f 0.28"C and -2.2 + 0.23"C afterwards (p < 0.02, t = 2.94, 
df = 9). 
Experiment 3: Mean core temperature at baseline was 37.6 + 0.18"C. The 
baseline thermic response to clonidine was -3.49 f 0.28"C (p < 0.00005, t = 
12.48, df = 6). Rechallenge with clonidine after one and two weeks revealed 
changes in the thermic response of +0.56 + 0.46"C (p > 0.30, t = 1.31, df = 
5) and +0.28 +- 0.26"C (p > 0.30, t = 1.1, df = 6), respectively. 
Discussion 
Chronic treatment with bright artificial light (11,500 lux) potently 
subsensitized the a2-receptor as inferred from measurement of clonidine- 
induced hypothermia. However, treatment with standard fluorescent light at 
an intensity of 300 lux had the opposite effect. This suggests that light 
intensity is a critical variable. Our observations argue against the 
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hypothesis that the effects of bright light result from an alteration of 
circadian rhythms due to constant light exposure. The intensity of light in 
the rats' cages in our vivarium is 300 lux. The animals demonstrate clear- 
cut circadian changes in motor activity and core temperature in response to 
turning the lights on or off. Thus, we propose that the results presented 
here are due to the effects of high intensity light rather than to light per 
se. The observation that the control sample exhibited a significant increase 
in its hypothermic response to clonidine of 0.8 + 0.28"C (p < 0.02) was 
unexpected. Certainly, significant blunting of the hypothermic response to 
clonidine following chronic exposure to 300 lux light would suggest that mere 
exposure to light or alterations in circadian rhythms affect subsensitivity 
of the mechanism mediating clonidine induced hypothermia. However, the 
results are opposite this. Bright light but not standard room light produced 
subsensitivity. Thus, the data are consistent with the hypothesis that 
bright artificial light affects subsensitivity of presynaptic a2 receptors. 
Our finding is consistent with reports that tricyclic antidepressants 
(21,22), monoamine oxidase inhibitors (231, electroconvulsive shock (241, and 
lithium carbonate (25) (treatments for depression) all subsensitize the a2- 
receptor. Our data do not prove that bright artificial light subsensitizes 
the presynaptic a2-receptor but are consistent with this possibility. Thus, 
the capacity to subsensitize a2-receptors is a property common to all 
treatments for depressive disorders which have been assessed for it. 
Patients with SAD are typically treated with full-spectrum light at an 
intensity of 2500 lux. There are advantages to using higher intensities of 
bright artificial light in preliminary studies. Our objective was to 
determine whether bright light, as opposed to standard room lighting, 
produces subsensitivity to the hypothermic effects of clonidine. Use of a 
high "dose" decreases the probability of accepting a false null hypothesis 
("bright artificial light does not produce subsensitivity to the thermic 
effects of clonidine"). Now that it has been demonstrated that treatment 
with full-spectrum light at an intensity of 11,500 lux results in decreased 
sensitivity to clonidine, and possibly subsensitivity of presynaptic a2- 
receptors, it would be reasonable to evaluate lower "doses" and the effects 
of administering light for circumscribed periods of time each day. These 
studies are now under way. 
The light unit we used delivers light at an intensity of 2500 lux at a 
distance of 122 cm from a patient's face. However, to deliver light at an 
intensity of 11,500 lux, the unit was suspended 50 cm above the animals. 
When placed this distance from the face of a patient, there is no discomfort. 
Thus, it would be feasible to change the current treatment protocols should 
studies suggest an intensity of light in excess of 2500 lux might be 
superior. 
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